Medications for Chronic Obstructive Airway Disease

8 results

  • breo ellipta

    (fluticasone furoate and vilanterol trifenatate)
    GlaxoSmithKline LLC
    BREO ELLIPTA is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma in patients aged 5 years and older. It is not to be used for the relief of acute bronchospasm.

  • incruse ellipta

    (umeclidinium)
    GlaxoSmithKline LLC
    INCRUSE ELLIPTA is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in patients.

  • nucala

    (mepolizumab)
    GlaxoSmithKline LLC
    NUCALA is indicated for the add-on maintenance treatment of severe asthma (ages 6+), chronic rhinosinusitis with nasal polyps (ages 18+), inadequate chronic obstructive pulmonary disease (COPD), eosinophilic granulomatosis with polyangiitis in adults, and hypereosinophilic syndrome in patients aged 12 and older.

  • perforomist

    (formoterol fumarate dihydrate)
    Mylan Specialty L.P.
    PERFOROMIST (formoterol fumarate) is indicated for long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, administered twice daily. It is not intended for acute worsening of COPD or for asthma treatment.

  • stiolto respimat

    (tiotropium bromide and olodaterol)
    Boehringer Ingelheim Pharmaceuticals Inc.
    STIOLTO RESPIMAT is indicated for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is not intended for acute COPD deteriorations or for the treatment of asthma.

  • trelegy ellipta

    (fluticasone furoate, umeclidinium bromide and vilanterol trifenatate)
    GlaxoSmithKline LLC
    TRELEGY ELLIPTA is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma in patients aged 18 and older. It is not intended for the relief of acute bronchospasm.

  • tudorza pressair

    (aclidinium bromide)
    AstraZeneca Pharmaceuticals LP
    TUDORZA® PRESSAIR® (aclidinium bromide) is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in patients.

  • yupelri

    (revefenacin)
    Mylan Specialty L.P.
    YUPELRI is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).